Research on targeted protein degradation is ongoing, with various approaches and applications being explored. Some studies focus on the role of specific factors, such as transcription factors, in this process, while others discuss the potential of proteolysis-targeting chimeras, or protacs, in treating certain types of cancer. The field appears to be advancing, with potential implications for the development of new therapies, including a reported fda approval for a protac therapy for breast cancer.